Tonix Pharmaceuticals stock halted ahead of FDA approval news
Adam H. Schechter, the President and CEO of Labcorp Holdings Inc (NYSE:LH), a $22.6 billion healthcare services provider, sold 5,643 shares of common stock on August 11, 2025, at a price of $266.78. The transaction amounted to $1,505,439. The stock has shown strong momentum, gaining over 21% in the past year.
Following the transaction, Schechter directly owns 93,319 shares of Labcorp Holdings Inc. This sale was executed pursuant to a Rule 10b5-1 trading plan. According to InvestingPro, the company’s stock is trading near its 52-week high, with management actively buying back shares. Analysts maintain a bullish outlook, with 11 analysts recently revising earnings estimates upward.
The transaction was reported in a Form 4 filing with the Securities and Exchange Commission (SEC) on August 13, 2025. For deeper insights into Labcorp’s valuation and growth prospects, InvestingPro offers exclusive analysis and 8 additional key insights not mentioned here.
In other recent news, Laboratory Corporation of America reported strong financial results for the second quarter of 2025. The company exceeded analysts’ expectations with an adjusted earnings per share of $4.35, surpassing the forecasted $4.17. Revenue also outperformed projections, reaching $3.53 billion against the anticipated $3.48 billion. Following these results, several analyst firms have adjusted their outlooks for the company. Jefferies raised its price target to $300, maintaining a Buy rating, citing a 1% top-line beat driven by the Base Business segment. Evercore ISI also increased its price target to $300, highlighting strong diagnostic growth from both organic sources and acquisitions. Leerink Partners set a new price target of $323, noting impressive earnings in the company’s pharma services and diagnostics business. These developments reflect positive sentiment among analysts regarding Laboratory Corporation of America’s recent performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.